Cashu FinanceCashu Finance
  • Terminal
  • Spotlight
  • Cashu Research
Log inSign Up
← Back to Terminal
  1. Stocks
  2. Healthcare
  3. NASDAQ
  4. SCYX

Market Cap: $23.96M

SI

SCYNEXIS, Inc.

SCYX
NASDAQUSD
Purchase SCYX
OverviewNewsAnalyst ReportsFinancialsPolitician TradesInsider TradesExecutive
Cashu FinanceCashu Finance

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

StocksAboutAdvertisersBrokersContact

Legal

Terms of ServicePrivacy Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Cashu Research is part of Cashu Technology Pty Ltd, which is an authorised representative (AR # 001318029) of Adviser Solutions Group Pty Ltd (ABN 88 601 875 521) (AFSL 485946) (ASG).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by Cashu Technologies Pty Ltd, any of their related body corporates or any other person. To the maximum extent possible, Cashu Technologies Pty Ltd, their related body corporates or any other person do not accept any liability for any statement in this material.

–
–(–)

Open

$4.77

Prev. Close

$3.79

High

$4.77

Low

$4.43

Company Profile

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

CEODavid Angulo
SectorHealthcare
IndustryMedical - Pharmaceuticals

Recently from Cashu

SCYNEXIS Reports Revenue Growth and Optimism for Future Antifungal Treatments Amid Market Demand

### SCYNEXIS Advances in Antifungal Treatments Amidst Growing Market Demand SCYNEXIS, Inc. makes significant strides in the pharmaceutical sector, particularly in antifungal therapies, as evidenced by…

Cashu Finance·8 months ago

Scynexis Expands Antifungal Pipeline to Meet Rising Market Demand for Innovative Treatments

Scynexis Advances Antifungal Pipeline Amidst Growing Market Demand Scynexis, a biotechnology company focused on innovative therapies for difficult-to-treat infections, is making significant strides in…

Cashu Finance·11 months ago

Scynexis Advances Antifungal Innovation and Strategic Collaborations to Strengthen Market Position

Scynexis Leverages Strategic Innovation to Enhance Market Position Scynexis, a clinical-stage biopharmaceutical company, focuses on developing innovative therapies for fungal infections and other seri…

Cashu Finance·11 months ago

Scynexis: Overview of Recent Developments and Market Performance

Please provide the content you would like me to summarize, and I'll be happy to assist you!

Cashu Finance·11 months ago
Employees
18
IPO DateMay 2, 2014
ExchangeNASDAQ
Exchange NameNASDAQ
CurrencyUSD
Headquarters & Contact
Address1 Evertrust Plaza
City / State / ZIPJersey City, NJ, 07302-6548
CountryUnited States
Phone201 884 5485
Websitehttps://www.scynexis.com